Novartis Ag

Nelson Guerreiro

Sebastien Jeay

Youzhen Wang

Stephane Ferretti

Ensar Halilovic

Christophe Meille

Jens Wuerthner

Astrid Jullion

Claire Fabre

The present invention relates to HDM2-p53 interaction inhibitors for use in the treatment of cancer, wherein the drug is administered by a high dose intermittent dosing regimen. The present invention relates in particular to the HDM2-p53 interaction inhibitor HDM20I and the dosing regimen di, d8 of a 4 week cycle.

Dose and regimen for HDM2-p53 interaction inhibitors

The present disclosure relates to use of GDF-15 as a safety biomarker for determining a toxicological effect of a Mdm2 inhibitor; an ex vivo method for determining a toxicological effect of a Mdm2 inhibitor in a subject, in particular for determining a likelihood of developing thrombocytopenia in a subject in response to administration of a dose of a Mdm2 inhibitor; methods of using a Mdm2 inhibitor in the treatment of cancer in a subject; a kit for use in predicting the likelihood that a patient having cancer will develop thrombocytopenia in response to a treatment with a dose of a Mdm2 inhibitor; a kit for use in treating a patient having cancer and related disclosure embodiments.

GDF-15 as a haematological toxicity biomarker

Growing community of inventors

Basel, Switzerland

Nelson Guerreiro